Harish Nagaraj, In Charge of the Integrated Molecular Imaging Centre at the Kenyatta University Teaching, Referral, and Research Hospital, shared a post on LinkedIn:
“Equal Treatment, Beyond Geographical Boundaries…
For years, many patients from Kenya and across East Africa had to travel overseas in search of advanced theranostic treatments such as Lutetium-177 PSMA for metastatic prostate cancer and Lutetium-177 DOTATATE for neuroendocrine tumors.
Today, that narrative is changing.
These promising, life-prolonging radioligand therapies are now available right here in Kenya.
Access to cutting-edge cancer care should never be determined by geography, financial ability to travel, or visa approvals. Patients deserve timely, world-class treatment closer to home surrounded by family, within their own healthcare system.
I am deeply grateful and proud to be part of this milestone journey in advancing theranostics locally. Bringing Lu-177 PSMA and DOTATATE therapy to Kenya is not just a clinical achievement it is a step toward equity in global oncology care.
The future of cancer treatment in Africa is not abroad. It is here. And it is growing.
NB: Consent obtained before posting the image.”
Other articles featuring Harish Nagaraj on OncoDaily.
